Researchers to test monthly vaginal ring for HIV prevention

Reuters – 17 hrs ago WASHINGTON (Reuters) - Two large clinical trials in Africa are ramping up to test the effectiveness of a vaginal ring that releases an HIV-fighting drug for a month or more, offering women at high risk a discreet way to protect themselves from the virus that causes AIDS.

The studies will test the effectiveness of a vaginal ring containing the antiretroviral drug dapivirine in thousands of women in several African countries to evaluate its ability to prevent new HIV infections and its long-term safety.

If effective, the ring will add "a long-acting, female-initiated technology to the existing toolkit of HIV prevention options," said Dr. Zeda Rosenberg, chief executive officer of International Partnership for Microbicides (IPM), a nonprofit group founded by Rosenberg which is developing the ring.

Because it only needs to be replaced once a month, the ring may help address some of the problems with getting women to consistently use vaginal gels each time they have sex, Rosenberg said during a briefing at the International AIDS Conference in Washington.

Irregular use is thought to be the reason a large study of the microbicidal gel containing the anti-HIV drug tenofovir failed to prevent infections in women in sub-Saharan Africa.

IPM has a royalty-free licensing agreement with Johnson & Johnson's Janssen unit in Ireland to use its dapivirine antiretroviral product in gel and ring forms to prevent HIV infections in low and middle income countries.

Dapivirine is part of a class of antiretroviral drugs that have long been used to treat HIV and prevent mother-to-child transmission of the virus.

NIH PARTNERSHIP

The IPM study will enroll 1,650 women aged 18 to 45, who will be randomly assigned to use the ring or a placebo in four sites in South Africa, with plans to expand to sites in Rwanda and Malawi.

It is being conducted in partnership with the U.S. National Institutes of Health-backed Microbicide Trials Network, which just started enrolling women in a separate trial called ASPIRE.

"Developing scientifically proven forms of HIV prevention that women can control is essential," said Dr. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Disease.

"Because the vaginal ring is a long-acting intervention, it has a potential added benefit in that women may find it relatively easy to use."

The ASPIRE study will test the ring in 3,476 women aged 18 to 45 in Malawi, South Africa, Uganda, Zambia and Zimbabwe.

Women in the studies will be offered condoms and counseling on HIV prevention, and taught how to insert the vaginal ring. At monthly visits, researchers will keep track of whether women are still using the ring and give them a replacement.

Those women who become pregnant during the study will discontinue use of the ring, and their safety and that of their child will continue to be monitored.

Dr. Saidi Kapiga of the London School of Hygiene and Tropical Medicine, who is coordinating the ring study in Africa and has also conducted tests of vaginal gels for HIV protection, said there are already signs that women prefer the new option.

"It is acceptable," Kapiga told the briefing. "The fact that they use it only once in four weeks was a major advantage."

Both trials are designed to detect at least a 60 percent reduction in HIV risk, but researchers said they hope for even better results, which are expected in 2015.

"If proven to be effective, I think this will really revolutionize prevention for women," Dr. Sharon Hillier, who heads the Microbicide Trials Network at the University of Pittsburgh School of Medicine, told the briefing.

(This story corrects Rosenberg's first name to Zeda in paragraph 3 and number of women in study to 1650 in paragraph 8)

(Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Eric Walsh)

View the Original article

Conservatism threatens AIDS prevention in LatAm: UN

"A poster showing the AIDS red ribbon in Mexico City in 2008. AIDS is under control in Latin America and the Caribbean but a conservative wave threatens efforts to prevent the spread of the deadly HIV virus, UN experts said Tuesday. (AFP Photo/Ronaldo Schemidt)" title

View the Original article

WHO endorses use of HIV medicines for prevention

Reuters – 2 hrs 27 mins ago NEW YORK (Reuters) - The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it, and suggested that poor and wealthy countries alike set up pilot projects to better understand the benefits.

The United Nations agency made its suggestion on Friday, four days after U.S. regulators approved use of Gilead Sciences Inc's Truvada for people who are not infected but may engage in sexual activity with HIV-positive partners. The concept is known as pre-exposure prophylaxis (PrEP).

Truvada, which combines the anti-HIV drugs tenofovir and emtricitabine in one pill, is widely used to treat people already infected with the virus that causes AIDS. The medicine, which costs almost $14,000 a year in the United States, is the first treatment also approved for prevention.

"WHO is encouraging countries wishing to introduce PrEP to first establish small projects to help public health workers to better understand and realize its potential benefits," the agency said in a statement. It said appropriate HIV medicines should be given to those at high risk of infection.

"These could include men or transgender women who have sex with men," the group said.

WHO spokeswoman Sarah Russell said the agency could not recommend specific drugs for prevention, but she said, "It needs to be a drug like Truvada that has been developed for prevention purposes."

Russell said WHO expects Gilead to make Truvada available at a deeply discounted price in some poor countries.

"We believe Gilead will bring the price down to about $100 per year per person" in those countries, she said in an interview.

Gilead officials could not immediately be reached for comment.

WHO noted that an international study called Partners PrEP has shown that HIV medicines are highly effective at preventing the illness in men and women whose partners are infected.

That study, conducted in Kenya and Uganda and funded by the Bill & Melinda Gates Foundation, involved taking a daily tablet containing tenofovir or tenofovir in combination with emtricitabine.

The U.N. agency said it would evaluate the outcomes of the small projects, along with evolving scientific evidence, before issuing its own detailed guidelines next year on the use of HIV treatments for prevention.

WHO said it was important that people taking HIV drugs for prevention are HIV-negative because otherwise drug resistant forms of HIV could evolve. The agency said they should also continue using condoms and faithfully take their medicines on a daily basis.

(Reporting By Ransdell Pierson; Editing by Toni Reinhold)

View the Original article

Truvada Gets FDA Nod for HIV Prevention

Other experts in the field agreed with this assessment.

"The approval of Truvada to prevent HIV infection in uninfected individuals who are at high risk of sexually acquired HIV infection is a significant development, providing an important addition to our toolkit of HIV prevention interventions," said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease. "However, it is critical to stress that Truvada as 'pre-exposure prophylaxis' should not be considered a stand-alone method, but should be used in conjunction with other proven HIV prevention strategies."

Not everyone was in favor of the approval. The AIDS Healthcare Foundation, a global organization involved in providing treatment to AIDS/HIV patients, strongly criticized the move, calling it irresponsible and saying Truvada's approval for this use would undermine current prevention efforts.

AHF president Michael Weinstein questioned whether the fact that support provided to study participants -- such as monthly HIV testing and intensive counseling -- would not be available to the general population would lead to decreased adherence to the drug regimen, and thus to the development of drug-resistant strains. Weinstein further cautioned that the drug's side effects on the kidneys and bones might be worth accepting in patients who needed to be treated for HIV, but were not worth the risk on otherwise healthy individuals.

"Today marks a catastrophe in the history of AIDS in America," he said.

While the AHF criticized the approval, a number of experts said there are many high risk individuals who won't use condoms but might take a daily pill.

"It's argued that PrEP is far more expensive than condoms, but it's a lot cheaper than a lifetime of HIV treatment," said Dr. Joel Gallant of the Johns Hopkins Center for Global Health. "If we can target PrEP to those at highest risk, PrEP is likely to be cost-effective."

More from ABC News HIV Prevention Pill Strengthens BondCritics Pan HIV Prevention PillMajor Breakthrough in HIV PreventionHIV Prevention Setback: Drug Trial HaltedAntiretroviral Drugs May Prevent HIV InfectionAIDS Prevention Pill Ineffective for Women More Video » Related Topics: HIV, Infectious Diseases, Sexually Transmitted Diseases, Food And Drug Administration, Gilead Sciences, Contraception, Side Effects, U.S., Allergy, Kidney Health Follow

View the Original article

FDA Approves Truvada as First HIV Prevention Drug

in addition, patients must also practice safe sex, go through risk reduction counseling and undergo regular HIV testing.

Because of the stringent guidelines the FDA is strengthening the box warnings that patients must be confirmed that they’re HIV negative and must be tested for the virus every three months while they’re on the medication.

View the Original article

US approves first-ever pill for HIV prevention

US approves first-ever pill for …

The first-ever daily pill to help prevent HIV infection was approved Monday by US regulators for use by healthy adults who are at risk for getting the virus that causes AIDS.

Truvada, made by Gilead Sciences in California, has been on the market since 2004 and was approved by the Food and Drug Administration for a new use as a tool to help ward off HIV, in combination with safe sex and regular testing.

The pill as pre-exposure prophylaxis (PrEP) has been hailed by some AIDS experts as a potent new tool against human immunodeficiency virus, while other health care providers are concerned it could encourage risky sex behavior.

In addition, the regimen is estimated to cost around $14,000 per year, making it out of reach of many.

"Truvada alone should not be used to prevent HIV infection," said Debra Birnkrant, director of the division of antiviral products at the FDA.

"Truvada as PrEP represents another effective, evidence-based approach that can be added to other prevention methods to help reduce the spread of HIV."

The FDA said Truvada should be used as "part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing."

Truvada was previously approved as a treatment for people infected with HIV to be used in combination with other antiretroviral drugs.

The decision by the FDA followed the advice of an independent panel in May that supported Truvada for prevention in uninfected people, after clinical trials showed it could lower the risk of HIV in gay men and heterosexual couples.

One study of men who were sexually active with other men but were not infected with the virus that causes AIDS found 44 percent fewer infections in those taking Truvada versus a placebo.

Those in the study who took the drug regularly had almost 73 percent fewer infections.

A second study on heterosexual couples in which one partner was infected with HIV and the other was not showed that Truvada reduced the risk of becoming infected by 75 percent compared with a placebo.

Common side effects were the same as experienced by people with HIV who were taking Truvada, and included diarrhea, nausea, abdominal pain, headache, and weight loss.

However, the adherence rate -- meaning how often people in the study actually took the drug daily -- was low in the study of men who have sex with men, at just 30 percent, Birnkrant said.

In the study of heterosexual partners, adherence was much higher, at between 80 and 90 percent.

Therefore, the drug label must include special instructions for health care providers on how to counsel potential users of the drug.

The drugmaker must also include a warning that Truvada for PrEP "must only be used by individuals who are confirmed to be HIV-negative prior to prescribing the drug and at least every three months during use."

As to concerns about whether the pill might boost risky sex practices and lead people to abandon condoms as a first line of protection, Birnkrant said the studies have not shown that so far.

"We don't really have any strong evidence to show that condoms were not used or that there was a decrease in condom use when Truvada was used," she told reporters.

The goal of the approval is to eventually cut back on the rate of new infections in the United States, which have stayed steady in recent years at about 50,000 annually, she said.

A key goal of the US strategy against HIV/AIDS, set forth in 2010, is to decrease the number of new infections by 25 percent by 2015.

"The hope is that over time it will decrease the rate of new infections or incidence in the United States," Birnkrant said.

The FDA approval drew the support of amfaR, The Foundation for AIDS Research.

"We know that Truvada, when taken as directed, works. Now we need to figure out how to properly use it to change the course of the epidemic," said a statement by amfaR chief executive Kevin Robert Frost.

However, the AIDS Healthcare Foundation described the move as "reckless," largely because the FDA recommends but does not explicitly require a negative HIV test prior to use.

"The FDA's move today is negligence bordering the equivalence of malpractice which will sadly result in new infections, drug resistance and serious side effects among many, many people," said AHF president Michael Weinstein.

ksh/sst

View the Original article

Studies Show Value of AIDS Drugs as Prevention

HealthDay – 1 hr 3 mins ago WEDNESDAY, July 11 (HealthDay News) -- Researchers have released the final results of two studies that suggest AIDS drugs can prevent exposed people in Africa from getting infected with HIV by their sexual partners. However, another study indicates that it's a tough job to convince African women who aren't at the highest risk to take preventive medications.

In the big picture, the studies show that "we have a new HIV-prevention strategy, one that's quite powerful but also depends on adherence," said Dr. Jared Baeten, an associate professor of global health at the University of Washington, in Seattle. "The next step is figuring out how to motivate people to take it."

The studies appeared online July 11 in the New England Journal of Medicine.

The general findings of the studies have been previously released, but only now has the research become available in a medical journal after going through a peer-review process.

Two studies offer promising details about the potential for the drugs to prevent -- although not all the time -- the transmission of HIV to heterosexual men and women from their infected partners.

One study in Kenya and Uganda looked at heterosexual couples -- almost all married -- in which one person was infected with HIV, the virus that causes AIDS. The uninfected partners were randomly assigned to take an inactive placebo or a once-daily dose of the drug tenofovir (Viread) or a tenofovir-emtricitabine combination (Truvada) for up to three years. Nearly 5,000 people completed the study.

Those who took Truvada had a 75 percent lower risk of becoming infected with HIV compared to those who received a placebo. The risk was 67 percent lower in those who took Viread compared to a placebo. Even in those who got the placebo, the overall risk of getting infected was low: 52 of 1,468, or a little more than 3 percent, did so.

Truvada treatment in the United States costs several thousand dollars a year, Baeten said, but the discounted price can be as cheap as 25 cents a day in Africa. The drug, which stops the AIDS virus from reproducing in people who are infected, appears to do the same thing in uninfected people who are exposed to the virus, he said. In their cases, the virus doesn't already have a foothold in the body so it dies off.

In this study, 10 percent or less of those who took the drugs reported side effects such as fatigue, diarrhea and nausea, and only in the first month.

The second study of 1,219 HIV-negative adults in Botswana looked at Truvada versus a placebo. Comparing the 33 participants who became infected during the trial -- nine people in the drug group and 24 people on a placebo -- the study found those who took Truvada were 62 percent less likely to become infected with HIV.

In this study, significant loss of bone mineral density was a side effect for participants receiving the drug, compared to those on a placebo.

Another study, in Kenya, South Africa and Tanzania, assigned 2,120 women at higher risk of HIV infection to receive Truvada or a placebo. However, there wasn't much difference in HIV infection rates between the two groups -- about 5 percent in both became infected.

Baeten explained the finding, saying many women stopped taking the drug, which prevented an accurate assessment of its effectiveness.

The next step in research into the use of the drugs to prevent infection is to "figure out how to make them work in the real world, outside of an intensive research setting," Baeten said. In the United States, for example, researchers are studying their use in gay men who are at high risk for infection.

As for condoms, another major player in HIV prevention, Baeten said the prevention drugs will add to their level of security or provide some protection in cases where people can't use condoms.

In an editorial accompanying the studies, two experts stressed that medications should never be viewed as a substitute for the condom.

"Although no evidence of increased risky sexual behavior or decreased condom usage was reported in these studies, we must ensure that pre-exposure prophylaxis does not indirectly encourage such behavior," wrote Dr. Myron Cohen of the University of North Carolina at Chapel Hill and Dr. Lindsey Baden of Brigham and Women's Hospital, Boston.

They added that more research is needed to properly assess who stands to benefit most from these drug regimens, the best timing and dosage, as well as any potential side effects from long-term use.

More information

For more about AIDS, visit the U.S. National Library of Medicine.

View the Original article

Studies Show Value of AIDS Drugs as Prevention

HealthDay – 1 hr 2 mins ago WEDNESDAY, July 11 (HealthDay News) -- Researchers have released the final results of two studies that suggest AIDS drugs can prevent exposed people in Africa from getting infected with HIV by their sexual partners. However, another study indicates that it's a tough job to convince African women who aren't at the highest risk to take preventive medications.

In the big picture, the studies show that "we have a new HIV-prevention strategy, one that's quite powerful but also depends on adherence," said Dr. Jared Baeten, an associate professor of global health at the University of Washington, in Seattle. "The next step is figuring out how to motivate people to take it."

The studies appeared online July 11 in the New England Journal of Medicine.

The general findings of the studies have been previously released, but only now has the research become available in a medical journal after going through a peer-review process.

Two studies offer promising details about the potential for the drugs to prevent -- although not all the time -- the transmission of HIV to heterosexual men and women from their infected partners.

One study in Kenya and Uganda looked at heterosexual couples -- almost all married -- in which one person was infected with HIV, the virus that causes AIDS. The uninfected partners were randomly assigned to take an inactive placebo or a once-daily dose of the drug tenofovir (Viread) or a tenofovir-emtricitabine combination (Truvada) for up to three years. Nearly 5,000 people completed the study.

Those who took Truvada had a 75 percent lower risk of becoming infected with HIV compared to those who received a placebo. The risk was 67 percent lower in those who took Viread compared to a placebo. Even in those who got the placebo, the overall risk of getting infected was low: 52 of 1,468, or a little more than 3 percent, did so.

Truvada treatment in the United States costs several thousand dollars a year, Baeten said, but the discounted price can be as cheap as 25 cents a day in Africa. The drug, which stops the AIDS virus from reproducing in people who are infected, appears to do the same thing in uninfected people who are exposed to the virus, he said. In their cases, the virus doesn't already have a foothold in the body so it dies off.

In this study, 10 percent or less of those who took the drugs reported side effects such as fatigue, diarrhea and nausea, and only in the first month.

The second study of 1,219 HIV-negative adults in Botswana looked at Truvada versus a placebo. Comparing the 33 participants who became infected during the trial -- nine people in the drug group and 24 people on a placebo -- the study found those who took Truvada were 62 percent less likely to become infected with HIV.

In this study, significant loss of bone mineral density was a side effect for participants receiving the drug, compared to those on a placebo.

Another study, in Kenya, South Africa and Tanzania, assigned 2,120 women at higher risk of HIV infection to receive Truvada or a placebo. However, there wasn't much difference in HIV infection rates between the two groups -- about 5 percent in both became infected.

Baeten explained the finding, saying many women stopped taking the drug, which prevented an accurate assessment of its effectiveness.

The next step in research into the use of the drugs to prevent infection is to "figure out how to make them work in the real world, outside of an intensive research setting," Baeten said. In the United States, for example, researchers are studying their use in gay men who are at high risk for infection.

As for condoms, another major player in HIV prevention, Baeten said the prevention drugs will add to their level of security or provide some protection in cases where people can't use condoms.

In an editorial accompanying the studies, two experts stressed that medications should never be viewed as a substitute for the condom.

"Although no evidence of increased risky sexual behavior or decreased condom usage was reported in these studies, we must ensure that pre-exposure prophylaxis does not indirectly encourage such behavior," wrote Dr. Myron Cohen of the University of North Carolina at Chapel Hill and Dr. Lindsey Baden of Brigham and Women's Hospital, Boston.

They added that more research is needed to properly assess who stands to benefit most from these drug regimens, the best timing and dosage, as well as any potential side effects from long-term use.

More information

For more about AIDS, visit the U.S. National Library of Medicine.

View the Original article

Anti-aging Prevention

June 27, 2012 by admin

Everyone desires to stay young and stunning. This really is why increasingly more people begin to appear to all of the latest anti-aging items and remedies available in the marketplace. When it comes to anti-aging practices, it’s essential to remember that an ounce of prevention is really worth a pound of remedy. This indicates that even prior to we begin to notice the visible signs of aging on our skin, we have to consider the essential precautions to make sure that we are in a position to maintain our youthful looking skin lengthier.

To prevent us from having to resort to very expensive anti-aging items and treatments, we need to embody a lifestyle that is friendly to our bodies and it is in a position to help prevent unneeded components that market the look of good lines and wrinkles on our skin as well.

We are able to begin our anti-aging way of life alter by eliminating dangerous components within our existence. Everybody knows that smoking is dangerous to their well being and it’s extremely harmful to our skin. No anti-aging routine will work successfully if we continue to smoke. Smoking takes its toll on our entire physique as well as on our skin. Studies show that smokers have a tendency to lose skin elasticity simpler than those that do not smoke. When our skin looses its elasticity, the fine lines and wrinkles appear.

Aside from using tobacco, it is also very important to avoid pollutants in common. This means that our anti-aging routine should include avoiding publicity to excessive dust and pollution in the environment. We’ll need to protect our skin from the harmful rays with the sun as well. This could be achieved through the proper moisturizing sun blocks. It should not quit there nevertheless simply because we’ll also have to be vigilant about the kinds of pollutants that we get through food and drink. We have to eat healthy and wisely so that we do not feed our bodies junk along with other harmful chemical substances and substances that will assist pace up the aging process.

Nevertheless if we begin to detect signs of aging in our skin, it is still not as well late to reverse the damage. Invest in good anti-aging products that battle anti-oxidants and totally free radicals while repairing and sustaining the skin’s correct elastin and collagen levels. These treatments ought to be combined with moisturizers and also the proper amount of rest to help our skin normally fix and regenerate new skin cell tissues.

Anti Aging

View the Original article

Magnesium is Vital for the Prevention of Osteoporosis

It has long been known that a magnesium rich diet of fresh fruit and vegetables is associated with better bone health, regardless of calcium intake.  A new study documents precise mechanisms explaining why magnesium is indispensable to healthy bones and the prevention of osteoporosis.

Osteoblasts are your important bone building carpenter cells.  The research shows that when they run low on magnesium they get in a bad mood and start cranking out a highly inflammatory signal (inducible nitric oxide – iNOS Inducible Nitric Oxide Synthase. This enzyme influences genes located in the neuro-immune and cardiovascular system and provides immune defense against pathogens and contributes to disease progression including neurogenic inflammation (iNOS2). ).  This results in two adverse outcomes for bones.

First, the iNOS Inducible Nitric Oxide Synthase. This enzyme influences genes located in the neuro-immune and cardiovascular system and provides immune defense against pathogens and contributes to disease progression including neurogenic inflammation (iNOS2). prevents the generation of new osteoblasts.  In essence the bones are reasoning that if there is not enough magnesium then the intake of nutrients for building bone is probably lacking, so there is no need for any more carpenters.  As far as bones are concerned the lack of magnesium is signaling a housing crisis and the magnesium-needing osteoblasts are headed for the unemployment line.

Second, the increase of iNOS Inducible Nitric Oxide Synthase. This enzyme influences genes located in the neuro-immune and cardiovascular system and provides immune defense against pathogens and contributes to disease progression including neurogenic inflammation (iNOS2). within bone triggers excessive activation of the demo crew known as osteoclasts Type of bone cell that removes old, damaged bone by the process bone resorption..  The adverse inflammatory increase of osteoclast activity combined with a relative decrease of osteoblast activity is the hallmark of bone loss, eventually leading to osteoporosis.

Magnesium deficiency is common in just about anyone struggling with virtually any ongoing health issue.  Magnesium is rapidly depleted by stress and lost in sweat (from exercise).  It is typical in individuals who feel agitated, irritated, anxious, and/or have trouble sleeping.  It isn’t the only reason for these issues but it certainly is a common finding in any of them.

In addition to a diet rich in fruits and vegetables, supplemental high quality magnesium (not magnesium oxide), ranging in daily doses from 200 mg on the low end up to 800 mg on the high end can be quite helpful in replenishing magnesium status.  Remember, your bones take the brunt of all the stressors in your life.  Adequate magnesium is basic for your bones and vital for many other aspects of health.

Share:
Supplements that contain magnesium
Related Entries:

Magnesium Supplements Lower Blood Pressure, Prevent Calcification
Magnesium Boosts BDNF and Synaptic Plasticity to Help Overcome Fear & Anxiety
Magnesium Supplementation Improves Sleep in Adults and Children
Magnesium Reduces Sudden Cardiac Death Risk in Women
Magnesium Deficiency Sets the Stage for Plaque in the Arteries
Magnesium – The Anti-Inflammatory Mineral

Other Health News

Pulling Data...

View the Original article

Report: State tobacco prevention funding lacking

"background-image:url('http://l1.yimg.com/bt/api/res/1.2/emYzL9d6anfTVuob39n9bQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTcwO3B5b2ZmPTA7cT04NTt3PTcw/http://l.yimg.com/os/152/2012/05/24/145211335-jpg_153429.jpg');" width

View the Original article

AIDS fight enters new phase with prevention pill

"background-image:url('http://l.yimg.com/bt/api/res/1.2/IHtfbSHqrx520beSaDI6NA--/YXBwaWQ9eW5ld3M7Y2g9MTk5Mztjcj0xO2N3PTI5MTE7ZHg9MDtkeT0wO2ZpPXVsY3JvcDtoPTEzMTtxPTg1O3c9MTkw/http://media.zenfs.com/en_us/News/ap_webfeeds/8391d1054a1e570d0f0f6a706700108e.jpg');" width

View the Original article

US health advisors mull AIDS prevention pill

"Bottles of antiretroviral drug Truvada. US health advisors are poised to decide Thursday on whether to recommend the drug, Truvada, as the first preventive pill against AIDS instead of just a treatment for infected people. (AFP Photo/Justin Sullivan)" title

View the Original article

FDA favors first drug for HIV prevention

"background-image:url('http://l2.yimg.com/bt/api/res/1.2/VJ6EKWFsMCaDftWtcKPZCw--/YXBwaWQ9eW5ld3M7Y2g9MTUwMDtjcj0xO2N3PTIxMDA7ZHg9MDtkeT0wO2ZpPXVsY3JvcDtoPTEzNjtxPTg1O3c9MTkw/http://media.zenfs.com/en_us/News/ap_webfeeds/017ec95dfd67110c0f0f6a70670012c5.jpg');" width

View the Original article

FDA Favors HIV Pill for Prevention

View the Original article

FDA review favors first drug for HIV prevention

"background-image:url('http://l2.yimg.com/bt/api/res/1.2/VJ6EKWFsMCaDftWtcKPZCw--/YXBwaWQ9eW5ld3M7Y2g9MTUwMDtjcj0xO2N3PTIxMDA7ZHg9MDtkeT0wO2ZpPXVsY3JvcDtoPTEzNjtxPTg1O3c9MTkw/http://media.zenfs.com/en_us/News/ap_webfeeds/017ec95dfd67110c0f0f6a70670012c5.jpg');" width

View the Original article

FDA favors first drug for HIV prevention

"background-image:url('http://l2.yimg.com/bt/api/res/1.2/VJ6EKWFsMCaDftWtcKPZCw--/YXBwaWQ9eW5ld3M7Y2g9MTUwMDtjcj0xO2N3PTIxMDA7ZHg9MDtkeT0wO2ZpPXVsY3JvcDtoPTEzNjtxPTg1O3c9MTkw/http://media.zenfs.com/en_us/News/ap_webfeeds/017ec95dfd67110c0f0f6a70670012c5.jpg');" width

View the Original article

Resveratrol Assists in the Primary Prevention of Cardiovascular Disease

A just published one year study of resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. supplementation in patients at high risk for cardiovascular disease found that resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. lowered multiple markers of inflammation (including CRP C-reactive protein. It is an acute phase protein that increases during systemic inflammation. It is a general way to assess cardiovascular disease risk. A more sensitive test for heart disease risk is hs-CRP, highly sensitive CRP. by 26 percent), as well as reduced clotting factors associated with stroke.  It boosted adiponectin Protein hormone that modulates metabolism including glucose and fatty acid catabolism. High levels are associated with low body fat. , which improves insulin function and reduces insulin resistance.  The researchers stated that their results showed for the first time that resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. could complement the gold standard therapy in the primary prevention of cardiovascular disease.

The results of this triple-blind, randomized, parallel, dose-response, placebo-controlled, one year follow up trial were published in the American Journal of Cardiology.  This new human study supports and confirms the extensive review of resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. as a cardiovascular mainline treatment that I reported on yesterday.

The dose of resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. in this study was not even very high.  It was 8 mg for the first six months and 16 mg for the next six months.  Daily doses of 100 mg to 600 mg of resveratrol Natural phenol or type of antioxidant found in red grapes, red wine. Research has shown beneficial effects as anti-cancer and anti-inflammatory agents along with supporting healthy blood sugar and cardiovasculature function. are in widespread consumer use and have been for years. 

Share:
Supplements that contain resveratrol
Related Entries:

Scientists Tout Resveratrol as a Primary Nutrient for Cardio Health
Resveratrol Helps Break Down Stored Fat
Resveratrol Helps Improve the Fitness of Your Fat
Is Resveratrol the Fountain of Youth?
Resveratrol Improves Insulin Function and Longevity

Other Health News

Pulling Data...

View the Original article

UCSD studies HIV prevention drug

The new one will enroll only men who have sex with men and transgender women who are at higher risk for HIV because they have multiple partners.

The study will use Truvada, a two-drug pill made by Gilead Sciences and approved by the U.S. Food and Drug Administration in 2004 to treat people with HIV. The company, which has applied for FDA approval to market it for HIV prevention, is providing the drug for free.

Study participants also will get counseling on reducing their risk for HIV.

Each of the three study teams will investigate slightly different areas.

UC San Diego will partner with San Diego County, Los Angeles County, the University of Southern California and the Long Beach health department to enroll 400 high-risk participants to get daily doses of Truvada.

All 400 will get regular counseling and health assessments; half also will get a daily text message reminder to take the pill.

View the Original article

Big Pharma Should Fund Research of Diabetes Drug for Cancer Prevention

This story comes from the Yahoo! Contributor Network, where individuals publish their unique perspectives on some of the world’s most popular websites.Do you have a story to tell? Become a Yahoo! contributor COMMENTARY

View the Original article